Skip to content

Monopar Therapeutics

US · MNPR #3671 by market cap Listed 2019
82.54 -1.24 -1.48%
Live - 5344 symbols - heartbeat 349s ago · 2026-10-08 10:00
Pre-market 84.54 +0.91%
After-hours 83.80 +0.02%
Overnight 83.03 -0.90%
Market cap
554.02M
P/B
4.23
EPS
-1.85
Reader sentiment Are you bullish or bearish on MNPR?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $104 to $130
    Market Newswire · 2026/5/15
  • Rating change
    H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125
    Market Newswire · 2026/7/22
  • Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145
    Market Newswire · 2026/9/11
  • Rating change
    A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $105
    Market Newswire · 2026/6/2
  • Rating change
    H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $105
    Market Newswire · 2026/6/3
  • A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $125 to $133
    Market Newswire · 2026/8/13
  • Rating change
    Cantor Fitzgerald Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $109
    Market Newswire · 2026/5/15
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON)
    TipRanks · 2026/4/21
  • Rating change
    Lake Street Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $103
    Market Newswire · 2026/6/30
  • Rating change
    Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101
    Market Newswire · 2026/6/3
  • H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125
    Market Newswire · 2026/9/22
  • Rating change
    BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117
    Market Newswire · 2026/7/1
  • Rating change
    Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/8/17
  • Rating change
    Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125
    Market Newswire · 2026/7/23
  • Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $123
    Market Newswire · 2026/9/28
  • Rating change
    Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/7/23
  • Rating change
    Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Cuts Target Price to $59.27
    Market Newswire · 2026/5/18
  • Rating change
    A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $130
    Market Newswire · 2026/6/30
  • H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
    TipRanks · 2026/9/22
  • Rating change
    BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $117
    Market Newswire · 2026/6/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 10:00:07 · For reference only, not investment advice and not tailored to your situation.